Havemeyer Place LP Takes Position in Medpace Holdings, Inc. $MEDP

Posted by Brian Himes on Jun 8th, 2026

Havemeyer Place LP purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 2,086 shares of the company’s stock, valued at approximately $1,172,000.

A number of other institutional investors and hedge funds have also made changes to their positions in MEDP. Optiver Holding B.V. purchased a new position in shares of Medpace in the 3rd quarter valued at $27,000. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new position in shares of Medpace in the 4th quarter valued at $30,000. Elyxium Wealth LLC purchased a new position in shares of Medpace in the 4th quarter valued at $30,000. Finally, Quarry LP purchased a new position in shares of Medpace in the 3rd quarter valued at $35,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

Negative Sentiment: Multiple law firms, including Rosen, Pomerantz, Schall, Faruqi & Faruqi, and others, reiterated that a class action has been filed against Medpace alleging violations of federal securities laws and investor harm. Article Title
Negative Sentiment: The lawsuits center on purchases made between April 22, 2025 and February 9, 2026, with investors urged to act before the June 8 lead-plaintiff deadline, keeping legal risk and uncertainty in focus. Article Title
Neutral Sentiment: One item noted a management change, with Medpace elevating Brad Hansman to an executive operations role, but this appears to be a routine corporate update with no immediate market-moving detail. Article Title

Insiders Place Their Bets

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This represents a 67.88% decrease in their position. The SEC filing for this sale provides additional information. 20.50% of the stock is owned by company insiders.

Medpace Price Performance

Medpace stock opened at $454.25 on Monday. The stock has a market capitalization of $12.97 billion, a price-to-earnings ratio of 28.55, a PEG ratio of 2.30 and a beta of 1.18. Medpace Holdings, Inc. has a 1-year low of $294.07 and a 1-year high of $628.92. The business has a fifty day moving average price of $456.73 and a 200-day moving average price of $508.39.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business’s quarterly revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Truist Financial cut their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Robert W. Baird cut their price target on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. BMO Capital Markets cut their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a report on Friday, February 13th. Finally, Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $467.08.

Read Our Latest Stock Report on MEDP

Medpace Company Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.